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Abstract
Background: Shoulder pain is a common complication of a stroke which can impede participation in rehabilitation
programs and has been associated with poorer outcomes. The evidence base for current medical and therapeutic
management options of hemiplegic shoulder pain is limited. This study will evaluate the use of suprascapular
nerve block injection as part of an interdisciplinary approach to the treatment of shoulder pain following stroke.
The technique has previously been proven safe and effective in the treatment of shoulder pain associated with
rheumatoid arthritis and degenerative shoulder conditions but its usefulness in a stroke population is unclear.
Methods/Design: A double blind randomised placebo controlled trial will assess the effect of a suprascapular
nerve block compared with placebo in a population of 66 stroke patients. The trial will measure effect of injection
on the primary outcome of pain, and secondary outcomes of function and quality of life. Measurements will take
place at baseline, and 1, 4 and 12 weeks post intervention. Both groups will continue to receive routine
physiotherapy and standard ward care.
Discussion: The results of this study could reduce pain symptoms in persons with mechanical shoulder pain post
stroke and provide improvement in upper limb function.
Trial Registration: This trial is registered with the Australian New Zealand Clinical Trials Registry (ANZCTR) -
ACTRN12609000621213.
Background
In any year, there are approximately 48,000 stroke
events amongst Australians. Shoulder pain is a distres-
sing complication of hemiplegia [1] and is reported as
one of the 4 most common medical complications of
stroke [2]. The prevalence of shoulder pain following
stroke has reported to be as high at 70% [3]. A more
recent prospective study of 327 consecutive stroke
patients concluded that almost a third of this population
developed moderate-severe shoulder pain after stroke
onset [4]. This more moderate figure reflects the 2006
paper by the same investigators, which focused on
patient’s perspectives on pain [5]. Each of these studies
highlight a correlation between pain and reduced func-
tional ability, as well as a higher incidence of depression.
Hemiplegic shoulder pain is associated with reduction in
functional use of the arm, interference with rehabilita-
tion and increased length of hospitalisation [6]. A
further complication of hemiplegic shoulder pain is
identified as a limitation to patient access to developing
technological upper-extremity rehabilitation techniques
[7].
Investigation into the cause of hemiplegic shoulder
pain has revealed a multifactorial aetiology [8]. Note is
made of the dependence on musculotendinous integrity
to provide stability of the shoulder complex. The most
common non-central, musculoskeletal aetiologies of
hemiplegic shoulder pain include adhesive capsulitis,
subluxation and rotator cuff patholgies, with up to one-
third of patients have multiple contributing factors [8].
Biomechanical changes result from a combination of
paralysis, fluctuation in muscle tone and prolonged
shoulder immobility which lead to postural malalign-
ment [1]. Dromerick et al [7] investigated the
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characteristics of hemiplegic shoulder pain, demonstrat-
ing that approximately 50% of the sample population
experienced pain in the vertical stabilisers of the
shoulder (biceps and supraspinatus). A 2006 evidence-
based medicine review concluded that subluxation may
be a cause of shoulder pain [9], though literature is
inconsistent regarding this association. It should be
noted that not all shoulder pain is associated with the
complications of limb flaccidity, and may be attributable
to spasticity or central-pain concepts.
There is lack of evidence to support the development
of clear clinical guidelines, as identified in an overview
of the challenges of managing shoulder pain after stroke
[10]. This paper concludes that further efforts are
required to examine intervention options. There have
been positive research results for the use of Functional
Electrical Stimulation [9], though a Cochrane Systematic
Review [11] of this topic did not support electrical sti-
mulation as an effective pain treatment. There is a lack
of Level 1 evidence for surgical interventions, motor
blocks and intra-articular corticosteroid injection.
Suprascapular nerve block is a safe and efficacious
treatment of shoulder pain associated with rheumatoid
arthritis and degenerative shoulder conditions [12]. The
objective of this study is to evaluate the use of Supras-
capular nerve block as part of an interdisciplinary
approach to the treatment of shoulder pain following
stroke. There is anecdotal report of successful use of
suprascapular nerve block in treating intractable hemi-
plegic shoulder pain [1], though to date no clinical trials
have been completed to form an evidence base.
Methods and design
The study design is a double blind randomised placebo
controlled trial will assess the effect of a suprascapular
nerve block compared with placebo in a population of
66 stroke patients (Figure 1). The trial will measure
effect of injection on the primary outcome of pain, and
secondary outcomes of function and quality of life. Mea-
surements will take place at baseline, and 1, 4 and 12
weeks post intervention. Both groups will continue to
receive routine physiotherapy and standard ward care.
Randomized controlled trial
Participants
Participants will be willing patients aged over 18 years
with a diagnosis of acute stroke within the previous 12
months and onset of hemiplegic shoulder pain post
stroke with a visual analogue scale score of > 30 mm
(100 mm scale). Exclusion criteria will include the
following:
▪ cognitive deficit that preclude patients from reliably
using subjective outcome measures scales (Mini-Mental
State Examination (MMSE) < 23)
▪ language deficits (inability to follow 2-stage com-
mand) or limited English language that preclude patients
from reliably using subjective outcome measures scales
▪ allergy to proposed injection agents (depo-medrol
40 mg and 0.5% bupivocaine hydrocholoride)
Setting/locations
Participants invited to participate in the study will be
recruited via the acute stroke and rehabilitation wards at
multiple hospitals sites across Adelaide, South Australia
including: Repatriation General Hospital, Flinders Medi-
cal Centre, The Queen Elizabeth Hospital, Hampstead
Rehabilitation Centre (Royal Adelaide Hospital), and
Griffith Rehabilitation Hospital. Ethics approval for the
study has been granted by the Human Research Ethics
Screening Recruitment 
Baseline Measurement 
Randomisation 
N =  66 
CONTROL 
Routine physiotherapy and 
standard ward care. 
+  
Placebo injection 
n = 33 
INTERVENTION 
Routine physiotherapy and 
standard ward care. 
+ 
Injection suprascapular nerve 
block  
n = 33 
Follow-up 1 week 
Follow-up 4 week 
Follow-up 12 week 
Follow-up 1 week 
Follow-up 4 week 
Follow-up 12 week 
Figure 1 Study Design - Randomised Controlled Trial.
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Committees of Flinders Medical Centre (61/09), Royal
Adelaide Hospital (09325), Repatriation General Hospi-
tal (09/09) and Queen Elizabeth Hospital (2009031).
Procedures
Participants will be assessed at baseline (following
recruitment) and then at 1, 4, and 12 weeks following
injection. In addition to demographics and classification
of stroke, these four assessments will include the follow-
ing measures:
(i) AbilityQ and ShoulderQ [13]
(ii) Modified Rankin Scale [14]
(iii) Croft Disability Questionnaire [15]
(iv) Euroquol [16]
(v) Visual Analogue Scale [16,17]
(vi) Application of 3 clinical tests shown to be pre-
dictive (98% probability) of hemiplegic shoulder pain
[18]
Following consent and baseline measures, participants
will be randomized to receive suprascapular nerve block
or placebo injection. Allocation will be managed by a
pharmacist external to the project.
Randomization
Participants will be assessed for eligibility, provided with
information about the study, provide informed consent,
be enrolled into the study and complete the baseline
assessment prior to allocation into the control or inter-
vention group. Participants will be assigned to the con-
trol or intervention group by a pharmacist external to
the project by simple randomisation generated by a
computer software program.
Intervention
Intervention Group The intervention group will receive
an a suprascapular nerve block injection to the back of
the affected shoulder (using depo-medrol 40 mg and
0.5% bupivivocaine hydrochloride). The technique pro-
posed for suprascapular nerve block [12] involves
approaching the patient from posterior aspect of
shoulder, which will ensure patient unable to visualise
syringe contents. The doctor administering the injec-
tions will not be blinded for safety reasons. This
approach has been used in a prior trial examining
suprascapular nerve blocks [12] Intervention participants
will continue to receive routine ward care of positioning
of limb, careful manual handling and physiotherapy/
occupational therapy suitable for the individual. The
treating team will remain blinded to the randomisation.
Control group The control group will receive an injec-
tion to the back of the shoulder of 5 ml normal saline
infiltrated subcutaneously after the 2 ml subcutaneous
1% lidocaine infiltration. Control participants will con-
tinue to receive routine ward care of positioning of
limb, careful manual handling and physiotherapy/
occupational therapy suitable for the individual. This
project does not involve the withholding of standard
treatment to any participant. The treating team will
remain blinded to the randomisation.
Outcomes
Outcomes will be assessed at 1 week, 4 weeks and 12
weeks by a physiotherapist blind to allocation. Proposed
primary outcome measure involves use of a 100-point
modified visual analogue scale (VAS) to assess pain [17].
This measure involves a 100 mm vertical line with peri-
odic demarcations, anchored with the written extremes
of subjective pain. Patients are asked to mark the sever-
ity of their current self-perceived pain on the scale, and
this is then recorded in millimetre readings. Research
suggests that a minimum change of 20 mm on the VAS
is required to demonstrate clinically significant lessening
of pain (initial reports >60 mm) [17]. Whilst a lesser
minimum change is accepted for lower initial pain
scores, we have chosen the stronger difference in the
context of best evidence in a population who is pre-
dicted to report higher pain scores.
Secondary outcomes of disability and quality of life
will be measured using the Modified Rankin Scale [14],
Croft Disability Questionnaire [15], and the EuroQol
Health Questionnaire [16]. The Croft Disability Ques-
tionnaire [15] includes 22 questions regarding disability
associated specifically with shoulder pain. This measure
is validated and chosen for this study as it more applic-
able in a more dependant sample population. Minimal
level of detectable change (90% confidence) will be 3
points. Secondary outcome of spasticity will be mea-
sured using the Modified Ashworth Scale (MAS). MAS
scores spasticity from 0-5.
Validity data will be collected for the AbilityQ and
ShoulderQ measures [13]. These tools were developed
by Lynn Turner-Stokes in 2006 to provide a sensitive
measure of shoulder pain which is responsible to change
in pain experience in a stroke population.
Sample size
Based on the data in the table 1[12], the standard devia-
tion of the change scores are assumed to be in the
range of 18-25. The attached table includes the esti-
mated required sample size for a range of standard
deviations and the three different clinically interesting
changes above.
Hence using a conservative estimate, it is expected
that a sample size of 26 participants per group (treat-
ment and placebo) will achieve a statistically and clini-
cally significant difference between the two groups
(power 80%, alpha 0.05). To allow for deaths and with-
drawals with a total attrition rate of 20%, a minimum
total of 66 participants will be recruited, 33 per group.
It is anticipated that recruitment of 66 participants (33
treatment, 33 placebo) size will take approximately 12
Allen et al. BMC Neurology 2010, 10:83
http://www.biomedcentral.com/1471-2377/10/83
Page 3 of 5
months and that each patient will be followed for 12
weeks.
Statistical analysis
Data will be exported into SPSS software for subsequent
analyses. A statistical analysis plan will be drafted at the
start of the project and all analyses will be carried out
after masking allocation.
The research questions will be assessed using an
intention to treat approach. Independent samples t-tests,
Mann-Whitney U tests and Chi-square test of associa-
tion will be used as appropriate to compare groups at
baseline. To determine differences between the groups
at the primary end-point, ANCOVA or logistic regres-
sion will be used with models adjusted according to
potential confounders.
Discussion
The protocol has been carefully designed with the aim
of achieving measurable, replicable and important
results. The methodological strength of the study
focuses around the use of placebo control, though the
contributors acknowledge that this may pose a recruit-
ment challenge. Considering that eligible patients have a
pain score of > 3, it is anticipated that patients may
decline participation on the grounds of not wanting to
risk 50/50 chance of randomisation to placebo group.
Taking this into account, greater time allowance has
been given for recruiting. Careful provision of informa-
tion prior to consent is vital in ensuring patient’s are
fully aware of implication of the randomisation. All
patients will be informed of their randomisation group
at the end of their trial participation and offered active
suprascapular nerve block if desired.
Another uncertainty is in establishing methodology to
catch probable timing of hemiplegic shoulder pain.
Lindgren’s 2007 population-based study on hemiplegic
shoulder pain found that the majority of the incidence
of pain occurred within the first 4 months post stroke
[4]. Our inclusion criteria allow for patients to be up to
twelve months post stroke, allowing for later incidences
of pain occurrence. Difficulty may arise, however, in
that ethics approval required injection in inpatient facil-
ity only. It is anticipated that many otherwise eligible
participants may be unidentified by inpatient recruit-
ment strategies.
Despite the realistic uncertainties outlined above, this
study will provide useful information pertaining to an
important topic. Shoulder pain is a common and debili-
tating symptom for a large number of people following
a stroke and currently there is poor evidence regarding
effective treatments. If the study shows that the supras-
capular nerve block is efficacious in management of
hemiplegic shoulder pain, it could potentially provide a
new treatment option for stroke patients.
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